10.14.20

Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

07.31.20

New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

07.01.20

New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health

Source: Horizon Therapeutics

05.14.20

New Data on the Pharmacokinetic Profile of Tepezza Reinforce the Labeled Dosing Regimen

Source: Horizon Therapeutics

05.11.20

US Physician Survey Illustrates the Impact of Thyroid Eye Disease on Patient Quality of Life

Source: Horizon Therapeutics

01.23.20

The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial of Tepezza for Thyroid Eye Disease

Source: Horizon Therapeutics

01.22.20

FDA Approves First Treatment for Thyroid Eye Disease

Source: FDA

12.16.19

FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

12.13.19

Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Disease

Source: Horizon Therapeutics

11.22.19

Horizon Therapeutics Launches New Online Community Connecting People Living With Thyroid Eye Disease

Source: Horizon Therapeutics

View more stories